Literature DB >> 16145056

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

Bruce E Johnson, Pasi A Jänne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16145056     DOI： 10.1200/JCO.2005.97.008

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Development and Validation of Biomarker Classifiers for Treatment Selection.

Authors:  Richard Simon
Journal:  J Stat Plan Inference       Date:  2008-02-01       Impact factor: 1.111

Review 2.  Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.

Authors:  Nagahiro Saijo; Masahiro Takeuchi; Hideo Kunitoh
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

Review 3.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

4.  EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.

Authors:  David E Gerber
Journal:  Drug Dev Res       Date:  2008-12-09       Impact factor: 4.360

5.  Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.

Authors:  Laura Casorzo; Mara Corigliano; Paolo Ferrero; Tiziana Venesio; Mauro Risio
Journal:  Diagn Pathol       Date:  2009-11-04       Impact factor: 2.644

6.  Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

Authors:  Ximing Tang; Marileila Varella-Garcia; Ana C Xavier; Erminia Massarelli; Natalie Ozburn; Cesar Moran; Ignacio I Wistuba
Journal:  Cancer Prev Res (Phila)       Date:  2008-08

Review 7.  Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis.

Authors:  Josh John Carlson; Louis P Garrison; Scott D Ramsey; David L Veenstra
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-09       Impact factor: 4.553

8.  Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.

Authors:  Toshihide Nishimura; Harubumi Kato; Norihiko Ikeda; Makoto Kihara; Masaharu Nomura; Yasufumi Kato; György Marko-Varga
Journal:  Int J Proteomics       Date:  2012-05-22

Review 9.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.

Authors:  K Bencardino; M Manzoni; S Delfanti; A Riccardi; M Danova; G R Corazza
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

10.  Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.

Authors:  Trevor J Pugh; Gwyn Bebb; Lorena Barclay; Margaret Sutcliffe; John Fee; Chris Salski; Robert O'Connor; Cheryl Ho; Nevin Murray; Barbara Melosky; John English; Jeurgen Vielkind; Doug Horsman; Janessa J Laskin; Marco A Marra
Journal:  BMC Cancer       Date:  2007-07-13       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.